Skip to content
OpenCapital
Get started

Apogee Therapeutics, Inc. APGE Q3 2025 earnings

Reported November 10, 2025 · Before market open

EPS-$1.11Beat by $0.01
EPS estimate-$1.12

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$10.0M
EPS estimate-$1.10

Financials

Q3 2025

Income statement

See full
Operating income-$71.3M-21.5%
Net income-$65.0M-32.6%
EPS (diluted)-$1.11-29.1%

Balance sheet

See full
Cash & equivalents$107.9M-9.1%
Total debt$9.9M-18.8%
Total assets$626.2M-19.3%

Cash flow

See full
Operating cash flow-$54.3M-27.6%
CapEx--100%
Free cash flow-$54.3M-25.4%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.37B-28.9%
Enterprise value$2.27B-29.6%

Returns & leverage

See full
Current ratio15.9×-0.5×

Versus estimates

Diluted EPS

Q1 2026-$1.06Beat by $0.06Q4 2025-$1.03Beat by $0.02
Q3 2025-$1.11Beat by $0.01
Q2 2025-$1.13Miss by $0.10Q1 2025-$0.95Beat by $0.24Q4 2024-$1.19Miss by $0.25

Ask the moment Apogee Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Apogee Therapeutics, Inc. report Q3 2025 earnings?
Apogee Therapeutics, Inc. (APGE) reported Q3 2025 earnings on November 10, 2025 before market open.
What were Apogee Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Apogee Therapeutics, Inc. reported eps of $-1.11 for Q3 2025.
Did Apogee Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-1.12 by $0.01.
How did Apogee Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 29.1% from $-0.86.
Where can I find Apogee Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-273250) and the 10-Q periodic report (0001193125-25-273260) directly on SEC EDGAR. The filing index links above go to sec.gov.